Program Summary
The Society for Immunotherapy of Cancer (SITC) hosted the Immunoprevention Virtual Summit on Monday, April 3, 2023 from 12–5 p.m. EDT. The summit was a free, public event that featured expert panel discussions, invited speakers, and attendee question and answer periods. The multi-stakeholder virtual summit featured over 25 panelists representing funding agencies, academic researchers, and industry.
Summit Organizers
Leisha Emens, MD, PhD – Ankyra Therapeutics
Sasha Stanton, MD, PhD – Providence Cancer Institute / Earle A. Chiles Cancer Research Institute
Philip Castle, PhD, MPH – National Cancer Institute
Mark Cobbold, PhD – AstraZeneca
Olivera (Olja) Finn, PhD, FAIO – University of Pittsburgh
Elizabeth Jaffee, MD, FAIO – Sidney Kimmel Cancer Center, Johns Hopkins University
Shizuko Sei, MD – National Cancer Institute
Problem Statement
Immune interception and prevention strategies harness the immune system to prevent invasive cancer at a stage when anti-tumor immunity is most effective. Despite its great potential to positively impact public health, there is a marked lack of education and awareness within the field of immuno-oncology on immunoprevention, and the field of cancer interception and prevention remains largely nascent. The scientific community must effectively address and develop the field of immunoprevention, improving patient outcomes and reducing the global burden of cancer.
Summit Goals & Objectives
The primary objective of the SITC Immunoprevention Virtual Summit was to highlight opportunities and challenges in the field of immunoprevention. Secondary goals include defining immunoprevention, with an emphasis on primary prevention; developing a roadmap to move forward in the field of immunoprevention; and establishing SITC as a home for researchers and healthcare providers interested in immunoprevention.
You can find more program details and the summit agenda here.